AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
Phase I trial reports objective response.
2003 JUL 3 - (NewsRx.com & NewsRx.net) -- EntreMed, Inc., (NASDAQ:ENMD) announced that National Cancer Institute (NCI) Phase I clinical data demonstrate that Panzem was well tolerated and produced an objective response in a patient with ovarian cancer.
This patient demonstrated a 67% reduction in tumor volume and a 78% reduction in CA125, which is a marker used to monitor disease in ovarian cancer patients. The study of 17 patients with advanced solid tumors was presented at the annual meeting of the American Society of Clinical Oncology.
According to the statement, these clinical findings are consistent with a preclinical study recently published by EntreMed, in collaboration with Emory's Winship Cancer Institute, showing that Panzem disrupts microtubules, the ...
- The National Cancer Institute Joins the Global Community of Scientists Now...
- Press release article from: PR Newswire September 4, 2008 700+ words
...announced today that the National Cancer Institute (NCI) has joined the...development. Specifically, the National Cancer Institute's Developmental Therapeutics...proud to work with the National Cancer Institute, a true leader in the...
- Celgene Corporation and The National Cancer Institute Initiate Clinical Trial...
- Press release article from: PR Newswire October 31, 2003 700+ words
...Celgene Corporation and the National Cancer Institute (NCI) announced today...agreement (CRADA) with The National Cancer Institute (NCI), a component...initial research, the National Cancer Institute will conduct additional...
- Photodynamic therapy in treating patients with skin cancer.(CLINICAL TRIAL...
- Magazine article from: Journal of Drugs in Dermatology Johnson, Hillary July 1, 2007 700+ words
Sponsors and Collaborators: Roswell Park Cancer Institute and National Cancer Institute (NCI). This randomized phase II trial is studying how well photodynamic therapy that includes aminolevulinic...
- National Cancer Institute Licenses Genomica's Pharmacogenomics Software.
- Press release article from: PR Newswire December 21, 1999 700+ words
...Discovery Manager(TM), to the National Cancer Institute. The addition of the National Cancer Institute supports Genomica's ongoing plan...TM) will be an asset to the National Cancer Institute by allowing it to accelerate its...
- InforSense and National Cancer Institute Enter Five-Year Agreement.
- Press release article from: Business Wire August 30, 2005 700+ words
...InforSense Ltd: --National Cancer Institute's Core Genotyping Facility...today announced that the National Cancer Institute (NCI), the US Federal...informatics grid." About The National Cancer Institute The National Cancer Institute...
- Tigris Pharmaceuticals Signs CRADA with the National Cancer Institute.
- Press release article from: PR Newswire May 15, 2008 700+ words
...Development Agreement (CRADA) with the National Cancer Institute (NCI) to collaborate on clinical and...xenograft studies in mice. About The National Cancer Institute The National Cancer Institute (NCI) is a part of the National Institutes...
- Delcath Systems Receives National Cancer Institute Approval to Expand Phase III...
- Press release article from: Business Wire May 30, 2007 700+ words
...DCTH) was informed today that the National Cancer Institute ("NCI") Institutional Review Board...with the Delcath System. About the National Cancer Institute The National Cancer Institute, established under the National Cancer...
- LabVantage Solutions' signs contract with National Cancer Institute Core...
- Press release article from: M2 Presswire October 9, 2002 700+ words
...signs contract with National Cancer Institute Core Genotyping Center...announced today that the National Cancer Institute (NCI), the Federal...21 CFR Part 11. About National Cancer Institute The National Cancer Institute...
